MAX
Chart AdvisorShares Psychedelics ETF
Simple chart
Extended chart
Main settings
| 10 year return | 0 |
| 3 year return | 32.79 |
| 5 year return | 0 |
| Annual return | 20.42 |
| Asset type | Equity |
| Average P/BV | 1.75 |
| Average P/E | 9.46 |
| Average P/S | 2.15 |
| Beta | 0.4 |
| Commission | 0.99 |
| Country | USA |
| Currency | usd |
| Div. yield | 0.31 |
| Foundation date | 2021-09-15 |
| ISIN code | US00768Y3624 |
| ISO country | US |
| Index | ACTIVE - No Index |
| Number of companies | 13 |
| Owner | AdvisorShares |
| Region | Global |
| Top 10 issuers, % | 57.12 |
| Website | link |
| Change per day | 0% 17.028 $ |
| Change per week | -1.6% 17.305 $ |
| Change per month | -0.83% 17.17 $ |
| Change per 3 month | -8.5% 18.61 $ |
| Change per half year | -16.42% 20.373 $ |
| Change per year | +20.42% 14.14 $ |
| Change per year to date | -1.06% 17.21 $ |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Top companies
| Title | Industry | Share, % | P/BV | P/S | P/E | EV/Ebitda | Dividend yield | |
| #1 |
 COMPASS Pathways plc |
Healthcare | 7.8644 | 1.65 | 0 | -1.91 | -0.69 | 0 |
| #2 |
 Alkermes plc |
Healthcare | 7.7698 | 3.32 | 3.13 | 13.27 | 9.4 | 0 |
| #3 |
 Relmada Therapeutics, Inc. |
Healthcare | 6.6722 | 0.39 | 0 | -0.21 | -0.12 | 0 |
| #4 |
 GH Research PLC |
Healthcare | 6.1726 | 2.04 | 0 | -17.08 | -6.96 | 0 |
| #5 |
 Neurocrine Biosciences |
Healthcare | 5.8272 | 5.49 | 6.03 | 41.64 | 22.57 | 0 |
| #6 |
 Supernus Pharmaceuticals, Inc. |
Healthcare | 5.2346 | 1.99 | 3.12 | 27.96 | 11.39 | 0 |
| #7 |
 Alto Neuroscience, Inc. |
Healthcare | 5.0798 | 1.93 | 0 | -1.26 | -2.06 | 0 |
| #8 |
 AbbVie |
Healthcare | 4.6133 | 92.87 | 6.64 | 96.15 | 25.13 | 2.97 |
| #9 |
 Johnson & Johnson |
Healthcare | 4.3527 | 4.83 | 3.88 | 24.53 | 14.43 | 2.79 |
| #10 |
 NRx Pharmaceuticals, Inc. |
Healthcare | 3.5295 | -0.69 | 0 | -1.21 | -1.15 | 0 |
Similar ETF
Other ETFs from the Management Company
| Title | Class | Category | Commission | Annual return |
| Equity | 0.83 | 61.39 | ||
| Equity | 0.84 | -0.91 | ||
| Equity | 1.18 | 8.94 | ||
| Equity | 0.95 | -5.36 | ||
| Equity | 1.28 | 23.28 | ||
| Multi-Asset | 1.71 | 11.95 | ||
| Equity | 1.03 | 50.52 | ||
| Equity | 0.9 | 14.31 | ||
| Equity | 1.1 | 21.77 | ||
| Multi-Asset | 1.51 | 21.53 | ||
| Equity | 0.75 | 11.26 | ||
| Equity | 2.84 | -17.15 | ||
| Equity | 1 | 7.68 | ||
| Equity | 1.01 | -9.01 | ||
| Equity | 0.99 | 1.65 |
Description AdvisorShares Psychedelics ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Based on sources: porti.ru
